Pricing Log in Create free account

Celldex Therapeutics, Inc. (CLDX) vs Viridian Therapeutics, Inc. (VRDN)

Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc. are both Biotechnology companies. Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc. are of similar size ($2.3B and $2.2B). Viridian Therapeutics, Inc. grew revenue faster over the last twelve months: 23,220.3% against −88.3%. Viridian Therapeutics, Inc. has the higher net margin (−544.1% vs −33,883.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Viridian Therapeutics, Inc. leads on 9 and Celldex Therapeutics, Inc. on 7.

Valuation

Metric CLDX VRDN Biotechnology median
P/E n/m n/m 8.50
P/S 2,415.94 28.86 9.71
P/B 3.00 3.64 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1,609.78 18.59 9.21
Earnings yield (15.80%) (17.71%) (33.15%)
Free cash flow yield (11.30%) (16.32%) (25.50%)

Profitability

Metric CLDX VRDN Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (36,733.82%) (569.68%) 0.00%
Net margin (33,883.77%) (544.06%) 0.00%
Free cash flow margin (27,294.81%) (471.04%) 0.00%
Return on equity (43.88%) (86.93%) (56.36%)
Return on assets (40.76%) (46.08%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLDX VRDN Biotechnology median
Revenue growth (TTM) (88.27%) 23,220.33% 6.02%
EPS growth (last fiscal year) (59.18%) (8.14%) 30.26%
Revenue growth, 5-year CAGR (26.93%) 132.18% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLDX VRDN Biotechnology median
Debt to equity 0.00 0.37 0.00
Current ratio 11.82 16.95 4.72
Net debt to EBITDA 1.78 2.23 0.96

Dividend

Metric CLDX VRDN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLDX VRDN Biotechnology median
Market cap 2.27b 2.22b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack